A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
M Fukuoka, H Niitani, A Suzuki, M Motomiya… - Journal of clinical …, 1992 - ascopubs.org
PURPOSE Camptothecin-11 (CPT-11) is a new semisynthetic derivative of CPT, and has
been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low …
been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low …
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
…, K Matsui, N Takifuji, S Kudoh, H Niitani… - JNCI: Journal of the …, 1991 - academic.oup.com
7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) is a novel
camptothecin derivative that has been selected for clinical evaluation because of its broad …
camptothecin derivative that has been selected for clinical evaluation because of its broad …
[PDF][PDF] Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere …
…, Y Segawa, Y Nishiwaki, Y Ohashi, H Niitani - Journal of clinical …, 2004 - academia.edu
Purpose Few randomized trials have demonstrated survival benefit of combination chemotherapy
involving new agents plus cisplatin compared with classic combination chemotherapy …
involving new agents plus cisplatin compared with classic combination chemotherapy …
Phase I study of recombinant human tumor necrosis factor
…, H Ichihashi, K Inoguchi, H Majima, H Niitani… - Cancer chemotherapy …, 1987 - Springer
A phase I clinical and pharmacokinetic study of recombinant human tumor necrosis factor (rH-TNF)
was conducted in a single dose schedule in 33 patients with advanced cancer. rH-…
was conducted in a single dose schedule in 33 patients with advanced cancer. rH-…
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
…, K Watanabe, T Onoshi, K Furuse, H Niitani… - Journal of clinical …, 1996 - ascopubs.org
PURPOSE This phase II study was conducted to evaluate the efficacy and toxicity of
moderate-dose (60 mg/m2) docetaxel in Japanese patients with previously untreated advanced (…
moderate-dose (60 mg/m2) docetaxel in Japanese patients with previously untreated advanced (…
S-1 plus cisplatin combination chemotherapy in patients with advanced non–small cell lung cancer: a multi-institutional phase II trial
…, Y Nakai, T Sugiura, M Kawahara, H Niitani - Clinical cancer …, 2004 - AACR
Purpose: To evaluate the efficacy and toxicity of a novel combination chemotherapeutic
regimen including cisplatin with an oral anticancer agent, S-1 that consisted of tegafur, 5-chloro-2…
regimen including cisplatin with an oral anticancer agent, S-1 that consisted of tegafur, 5-chloro-2…
Phase I study of E7010
…, A Yoshimura, M Fukuoka, K Furuse, H Niitani - Cancer chemotherapy …, 1998 - Springer
E7010 is a novel sulfonamide which was discovered using slow-growing colon 38 carcinoma
cells as a screening model. E7010 exhibits a broad spectrum of antitumor activity against …
cells as a screening model. E7010 exhibits a broad spectrum of antitumor activity against …
A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
…, E Kinuwaki, M Motomiya, Y Nishiwaki, H Niitani… - Lung cancer, 1994 - Elsevier
To evaluate the effectiveness of vinorelbine (NVB) in patients with non-small cell lung cancer
(NSCLC), a late Phase II study was conducted. A total of 80 patients with Stage III or IV …
(NSCLC), a late Phase II study was conducted. A total of 80 patients with Stage III or IV …
A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer
T Masuno, S Kishimoto, T Ogura, T Honma, H Niitani… - Cancer, 1991 - Wiley Online Library
The efficacy and safety of intrapleural LC9018 (Yakult Co. Ltd., Tokyo, Japan) with or
without doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) were evaluated in a …
without doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) were evaluated in a …
Phase I study of TZT‐1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
…, M Andoh, M Kawahara, M Fukuoka, H Niitani - Cancer …, 2009 - Wiley Online Library
TZT‐1027 is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. A
phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT‐1027, …
phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT‐1027, …